Palisade Bio, Inc. (PALI)
NASDAQ: PALI · Real-Time Price · USD
2.100
+0.100 (5.00%)
At close: Oct 9, 2025, 4:00 PM EDT
2.150
+0.050 (2.38%)
After-hours: Oct 9, 2025, 4:16 PM EDT
Palisade Bio Employees
Palisade Bio had 8 employees as of December 31, 2024. The number of employees decreased by 1 or -11.11% compared to the previous year.
Employees
8
Change (1Y)
-1
Growth (1Y)
-11.11%
Revenue / Employee
n/a
Profits / Employee
-$1,480,625
Market Cap
19.15M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 8 | -1 | -11.11% |
Dec 31, 2023 | 9 | -3 | -25.00% |
Dec 31, 2022 | 12 | -1 | -7.69% |
Dec 31, 2021 | 13 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
PALI News
- 7 days ago - Palisade Bio Announces Closing of Upsized $138 Million Public Offering of Common Stock and Including Full Exercise of Over-Allotment Option - GlobeNewsWire
- 8 days ago - Palisade Bio Announces Pricing of Upsized $120 Million Underwritten Public Offering of Common Stock - GlobeNewsWire
- 13 days ago - Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum - GlobeNewsWire
- 22 days ago - Palisade Bio Reports Positive PALI-2108 Phase 1b Clinical Data - GlobeNewsWire
- 4 weeks ago - Palisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn's Disease (FSCD) - GlobeNewsWire
- 6 weeks ago - Palisade Bio Releases Virtual Investor KOL Connect Segment on FSCD and Lead Candidate PALI-2108 - GlobeNewsWire
- 2 months ago - Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108 - GlobeNewsWire
- 2 months ago - Palisade Bio Receives Notice of Allowance for Composition of Matter Patent Covering Lead Product Candidate PALI-2108 in China - GlobeNewsWire